JPM vs NP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial weakness. While revenue growth remains strong at 28.8%, the company exhibits a catastrophic Price/Book ratio of -16.29, suggesting negative shareholders' equity. Liquidity is precarious with a Quick Ratio of 0.21, and a sharp Q/Q earnings decline of 26.1% contradicts the bullish analyst consensus. The stock is fundamentally overvalued on a Price/Sales basis (20.69x) and lacks any deterministic value floor.
Compare Another Pair
Related Comparisons
JPM vs NP: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Neptune Insurance Holdings Inc. (NP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.